KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals International PLC - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of July 17, 2026, KNSA stock price climbed to $63.95 with 692,950 million shares trading.

KNSA has a beta of -0.45, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.02 to the broad based SPY ETF.

KNSA has a market cap of $4.92 billion. This is considered a Mid Cap stock.

Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $214 million in Revenue and $.27 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.11.

In the last 3 years, KNSA traded as high as $67.53 and as low as $14.12.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): VTI, IWM, VB, VBK, IWO.

KNSA has outperformed the market in the last year with a return of +121.7%, while the SPY ETF gained +19.5%. In the last 3 month period, KNSA beat the market returning +42.4%, while SPY returned +4.9%. However, in the most recent 2 weeks KNSA has underperformed the stock market by returning -0.9%, while SPY returned -0.2%.

KNSA support price is $59.22 and resistance is $63.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.